Industry wants broader health technology assessments, says new report
This article was originally published in Scrip
Executive Summary
Health technology assessment (HTA) should be broader, says a new report commissioned by the R&D-based pharmaceutical industry. Assessments that take on the views of a wider stakeholder groups or incorporate more technologies, for example, would provide a wider evidence base to support the use of drugs under scrutiny, said Edith Frénoy, director of market access at the European Federation of Pharmaceutical Industry Associations (EFPIA).